Clopidogrel for Proteinuria Reduction in Focal Segmental Glomerulosclerosis: Phase 2 Trial Design-Reference-Cited by-同舟云学术

Clopidogrel for Proteinuria Reduction in Focal Segmental Glomerulosclerosis: Phase 2 Trial Design

Published:2024-02 Issue:2 Volume:9 Page:478-481
ISSN:2468-0249
Container-title:Kidney International Reports
language:en
Short-container-title:Kidney International Reports

Author:

Daniel-Fischer Lisa,Antlanger Marlies,Cejka Daniel,Eller Kathrin,Gauckler Philipp,Odler Balazs,Rudnicki Michael,Säemann Marcus D.,Schmidt Alice,Sunder-Plassmann Gere,Wiesholzer Martin,Windpessl Martin,Zitt Emanuel,Koenig Franz,Greenbaum Larry A.,Kronbichler Andreas,Aufricht Christoph

Publisher

Elsevier BV

Subject

Nephrology

Reference8 articles.

1. Interventions for focal segmental glomerulosclerosis in adults;Hodson;Cochrane Database Syst Rev,2022

2. A systems pharmacology workflow with experimental validation to assess the potential of anakinra for treatment of focal and segmental glomerulosclerosis;Boehm;PLoS One,2019

3. Computational drug repositioning of clopidogrel as a novel therapeutic option for focal segmental glomerulosclerosis;Gebeshuber;Transl Res,2023

4. Antiplatelet agents for chronic kidney disease;Natale;Cochrane Database Syst Rev,2022

5. P2Y12 inhibitor clopidogrel inhibits renal fibrosis by blocking macrophage-to-myofibroblast transition;Chen;Mol Ther,2022

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug repurposing for glomerular diseases: an underutilized resource;Nature Reviews Nephrology;2024-07-31

2. Big Data-Enabled Repurposing of Clopidogrel for Focal Segmental Glomerulosclerosis Using Network Biology;Drug Repurposing;2024